According to filings with the U.S. Securities and Exchange Commission, Turn Biotechnologies is raising $43,867,224.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Anja Krammer played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Turn Biotechnologies
Aging has been called the emperor of all maladies. Turn Bios goal is to address multiple aging-related indications using a single powerful reprogramming therapy that turns old cells young again, aiding in the rejuvenation of an aged human body. In 2013, a paper in Cell (The hallmarks of aging, pez-Otin et al.,) proposed nine key Hallmarks of Aging that are causes of the general phenotype we refer to as aging. Our team recognized that it would be necessary to turn back the clock on each of these hallmarks and so set out to develop the technology to do just that. The task was achieved by a using a proprietary cocktail of transiently-administered rejuvenation factors that have now been shown to reverse eight of the nine hallmarks. Join us as we embark on the task to turn back time.

To learn more about Turn Biotechnologies, visit http://www.turn.bio/

Contact:
Anja Krammer, Chief Executive Officer
833-887-6246

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.